Gliklazid MB Pharmstandard, 60 mg 30 pcs

Orderal hypoglycemic agent, sulfonylurea derivative of the II generation. Stimulates insulin secretion by pancreatic β-cells. Increases the sensitivity of peripheral tissues to insulin. Apparently stimulates activity of intracellular enzymes (in particular, muscle glycogen synthetase). Reduces the time interval from the moment of food intake to the beginning of insulin secretion. Restores the early peak of insulin secretion, reduces the postprandial peak of hyperglycemia.

Glyclazide reduces platelet adhesion and aggregation, slows the development of parietal thrombus, increases vascular fibrinolytic activity. It normalizes vascular permeability.

It has anti-atherogenic properties: lowers the blood concentration of total cholesterol (CH) and LDL, increases the concentration of HDL and reduces the amount of free radicals. Prevents the development of microthrombosis and atherosclerosis. Improves microcirculation. Reduces the sensitivity of blood vessels to adrenaline.

In diabetic nephropathy with long-term use of gliclazide there is a significant reduction of proteinuria.

Indications

Type 2 diabetes mellitus with insufficient effectiveness of diet therapy, physical activity and weight loss.

Prevention of complications of type 2 diabetes mellitus: reducing the risk of microvascular (nephropathy, retinopathy) and macrovascular complications (myocardial infarction, stroke).

Pharmacological effect

Oral hypoglycemic agent, sulfonylurea derivative of the second generation. Stimulates insulin secretion by pancreatic β-cells. Increases the sensitivity of peripheral tissues to insulin. Apparently, it stimulates the activity of intracellular enzymes (in particular, muscle glycogen synthetase). Reduces the time interval from the moment of food intake to the onset of insulin secretion. Restores the early peak of insulin secretion, reduces the postprandial peak of hyperglycemia.

Gliclazide reduces platelet adhesion and aggregation, slows down the development of mural thrombus, and increases vascular fibrinolytic activity. Normalizes vascular permeability.

It has anti-atherogenic properties: it lowers the concentration of total cholesterol (C) and LDL-C in the blood, increases the concentration of HDL-C, and also reduces the number of free radicals. Prevents the development of microthrombosis and atherosclerosis. Improves microcirculation. Reduces the sensitivity of blood vessels to adrenaline.

In diabetic nephropathy, with long-term use of gliclazide, a significant decrease in proteinuria is observed.

Special instructions

Treatment with Gliclazide MB tablets is carried out only in combination with a low-calorie, low-carbohydrate diet. It is necessary to regularly monitor blood glucose levels on an empty stomach and after meals, especially in the first days of treatment with the drug.

Active ingredient

Gliclazide

Composition

Active substance:

Contraindications

– hypersensitivity to gliclazide or any of the excipients of the drug, to other sulfonylurea derivatives, to sulfonamides;
– diabetes mellitus type 1;
– diabetic ketoacidosis, diabetic precoma, diabetic coma; . – severe renal and/or liver failure;
– pregnancy and lactation;
– age up to 18 years;
– taking miconazole;
– congenital lactose intolerance, lactase deficiency or glucose-galactose malabsorption.

It is not recommended to use the drug simultaneously in combination with phenylbutazone or danazol.

Side Effects

Hypoglycemia (in case of violation of the dosage regimen and inadequate diet): headache, increased fatigue, hunger, increased sweating, severe weakness, palpitations, arrhythmia, increased blood pressure, drowsiness, insomnia, agitation, aggressiveness, anxiety, irritability, impaired concentration, inability to concentrate and delayed reaction, depression, visual impairment, aphasia, tremor, paresis, sensory disorders, dizziness, feeling of helplessness, loss of self-control, delirium, convulsions, shallow breathing, bradycardia, loss of consciousness, coma.

Interaction

Gliclazide enhances the effect of anticoagulants (warfarin); dose adjustment of the anticoagulant may be required.

Overdose

Symptoms: hypoglycemia, impaired consciousness, hypoglycemic coma.

Storage conditions

List B. In a dry place, protected from light, at a temperature not exceeding 25 ° C.

Shelf life

3 years.

Manufacturer

Pharmstandard-Leksredstva, Russia